Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Does intensive statin therapy lower mortality and cardiovascular event risk in patients with acute coronary syndrome?

Nature Clinical Practice Cardiovascular Medicine volume 2, pages 10–11 (2005)Cite this article

boxed-textde Lemos JA et al. for the A to Z Investigators (2004) Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 292: 1307–1316

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Schwartz GG et al. (2001) Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 285: 1711–1718

    Article  CAS  Google Scholar 

  2. Cannon CP et al. (2004) Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350: 1495–1504

    Article  CAS  Google Scholar 

  3. Nissen SE (2004) High-dose statins in acute coronary syndromes: not just lipid levels. JAMA 292: 1365–1367

    Article  CAS  Google Scholar 

  4. Ridker PM et al. (2002) Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 347: 1557–1565

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Hannah Camm, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Medical Director of the Cleveland Clinic Cardiovascular Coordinating Center, Cleveland Clinic Foundation, Cleveland, OH, USA

    Steven E Nissen

Authors
  1. Steven E Nissen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Steven E Nissen.

Ethics declarations

Competing interests

SE Nissen receives research support and is a consultant to Pfizer Inc., Sanofi-Aventis Group, Sankyo Pharma Inc., Takeda Ltd., Astra Zeneca, Atherogenics Inc., Eli Lilly and Company and Lipid Sciences Inc.. In addition, SE Nissen is a consultant for GlaxoSmithKline Inc., Forbes Medi-Tech Inc., Novartis, Haptoguard, Novo-Nordisk and Vasogenix Pharmaceuticals Inc.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nissen, S. Does intensive statin therapy lower mortality and cardiovascular event risk in patients with acute coronary syndrome?. Nat Rev Cardiol 2, 10–11 (2005). https://doi.org/10.1038/ncpcardio0066

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpcardio0066

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing